

Press Release

Media Contact
Matthias Link
T +49 6172 609-2872
matthias.link@fresenius.com

**Contact for analysts and
investors**
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com

www.freseniusmedicalcare.com

May 23, 2019

S&P upgrades Fresenius Medical Care to BBB with stable outlook

Fresenius Medical Care, the world's largest provider of dialysis products and services, today announced that Standard & Poor's has upgraded Fresenius Medical Care's corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius Medical Care is rated investment grade by the three leading rating agencies Standard & Poor's (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,971 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 336,716 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.